APLENZIN

LOE Approaching

bupropion hydrobromide

NDAORALTABLET, EXTENDED RELEASE

Approved

Apr 2008

Lifecycle

LOE Approaching

Competitive Pressure

25/100

Clinical Trials

1

Mechanism of Action

unknown, as is the case with other antidepressants. However, it is presumed that this action is mediated by noradrenergic and/or dopaminergic mechanisms. Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine and does not inhibit monoamine oxidase or the…

Indications (5)

major depressive disorder (MDD)seasonal affective disorder (SAD)defined by the Diagnostic Statistical Manual (DSM)seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (SAD)

Clinical Trials (1)

NCT02129751Phase 4Not Yet Recruiting

Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder

Started Jun 2026

Loss of Exclusivity

LOE Date

Jun 27, 2026

3 months away

Patent Expiry

Jun 27, 2026

Patent Records (5)

Patent #	Expiry	Type	Use Code
7241805	Jun 27, 2026	Product	—
7569610	Jun 27, 2026		U-997
7572935	Jun 27, 2026	Product	—
7585897	Jun 27, 2026	Product	—
7645802	Jun 27, 2026	Product	—

Company

NJ - Bridgewater

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers